The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments
Abstract
This editorial refers to ‘Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study’†, by T.K. Schramm et al., on page 1900 As illustrated most recently by the controversy surrounding the myocardial infarction risk associated with rosiglitazone,1 substantial uncertainty remains regarding the effects of different glucose-lowering drug classes and, importantly, different drugs within each class on cardiovascular (CV) risk and mortality outcomes in patients with type 2 diabetes (T2DM). In the setting of the ongoing proliferation of anti-hyperglycaemic therapeutic classes and formulations with myriad therapeutic options for the treatment of T2DM presently available,2 this uncertainty has prompted regulatory agencies in both Europe and the USA to reassess the approval process for new T2DM medications, with changes focused primarily on excluding with a specified degree of statistical certainty incremental CV risk prior to new drug approval.3 Long-term randomized clinical outcome trials with both new and presently available medications are recommended, but not mandated. In the absence of definitive CV risk assessment from randomized trials for presently available drug classes and individual drugs within each class, critical analyses of existing databases are both imperative and informative.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, the long-lasting uncertainty about the CV safety of sulphonylureas may no longer be clinically relevant for glimeperide, at least in patients with a shorter duration of diabetes like those enrolled in the CAROLINA trial (median duration of T2DM ∼6 years).182”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [182]
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Sulfonylurea Stimulation of Insulin Secretion
Proks, P., Reimann, F., Green, N., Gribble, F., & Ashcroft, F. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s368 · Cited by 510
Research works printed but not linked: 1
- Goldner, 1971, JAMA, 218, 1400, 10.1001/jama.1971.03190220020005 · doi:10.1001/jama.1971.03190220020005 · Paper page
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationGao, P., Yee, R., Gula, L., Krahn, A. D., Skanes, A., Leong-Sit, P., Klein, G. J., Stirrat, J., Fine, N., Pallaveshi, L., et al. (2012) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.111.971549 · Cited by 212
KATPChannels and Cardiovascular Disease: Suddenly a Syndrome
Nichols, C. G., Singh, G. K., & Grange, D. K. (2013) · Circulation Research · doi:10.1161/circresaha.112.300514 · Cited by 171
“This debate is still not resolved.(170,171) Given the new realization of the SUR2-dependent basis of Cantu syndrome, the opportunity immediately presents itself for the use of K ATP channel inhibitors as a potential magic bullet therapy, because they have proven in the treatment of Kir6.”
BackgroundMogensen, U. M., Andersson, C., Fosbøl, E. L., Schramm, T. K., Vaag, A. A., Scheller, N. M., Torp-Pedersen, C. T., Gislason, G., & Køber, L. (2014) · Diabetologia · doi:10.1007/s00125-014-3372-z · Cited by 54
“In other studies on clinical outcome data, glibenclamide was associated with increased mortality when compared with glimepiride and gliclazide [10, 11], and it has been speculated that the increased mortality associated with intensive therapy in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study [15]…”
ResultAdenosine Triphosphate-Sensitive Potassium Currents in Heart Disease and Cardioprotection
Nichols, C. G. (2016) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2016.01.005 · Cited by 59
Metadata
- Authors
- Gore, M. O., & McGuire, D. K.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- McGuire, D. K.
- ORCID
- Gore, M. O.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-06
- Volume
- 32
- Issue
- 15
- Pages
- 1832-1834
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2003077957
- Cited by
- 23
- References
- 20
- Citations by year
- 2023: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 4 · 2013: 2 · 2012: 3
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular risk, drug class effect, insulin secretagogues, metformin, rosiglitazone, mortality, drug approval regulation
- MeSH terms
- Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Hypoglycemic Agents, Insulin, Metformin, Myocardial Infarction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. https://app.cochat.ai/papers/10.1093/eurheartj/ehr019
- The paper
- Gore, M. O., & McGuire, D. K. (2011). Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. European Heart Journal. https://doi.org/10.1093/eurheartj/ehr019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.